Log inSign up
Pharma-Marketing.comPharma-Marketing.com
  • Industry
  • Digital Health & AI
  • Channels
  • People
  • Agencies
  • Glossary
Log inSign up
  • Terms of Service
  • Privacy Policy
  • Cookie settings
  • Imprint
Pharma-Marketing.com


All rights reserved.

We use AI tools in the creation of certain content.

Pharma Marketing

Data-privacy settings

We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.

AcceptEssential cookie
NameData-privacy settings
ProviderPharma-Marketing.com
PurposeStores these privacy settings in your browser.
Privacy policyPrivacy policy
Cookiespm_data_privacy
Cookie expiration180 days
Accept
NameGoogle Analytics
ProviderGoogle LLC
PurposeCookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_ga, _gat, _gid
Cookie expiration2 Years
Accept
NameGoogle Ads
ProviderGoogle LLC
PurposeCookies by Google Ads are used for advertising and targeting purpose.
Privacy policyPrivacy policy
Cookies__gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration2 Years
Accept
NameFacebook
ProviderFacebook Inc.
PurposeCookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_fbp, fr
Cookie expiration2 Years
Accept
NameMicrosoft Clarity
ProviderMicrosoft Corporation
PurposeCookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Privacy policyPrivacy policy
Cookies_clck, _clsk, CLID, ANONCHK, MR, MUID, SM
Cookie expirationUp to 1 Year
© Image: Moderna

Thursday, August 20, 2026

Moderna reports positive Phase 3 melanoma data

Moderna has reported positive topline results from the Phase 3 INTerpath-001 trial. The study evaluated intismeran autogene, an investigational individualized neoantigen therapy based on mRNA, in combination with pembrolizumab as adjuvant treatment for patients with completely resected Stage IIB to IV melanoma.

The company said the study was conducted with Merck. Moderna framed the outcome as an important step for a treatment concept that uses information from an individual tumor to design a patient-specific cancer therapy.

Comparison with standard treatment

The combination was tested against pembrolizumab alone, which is a current standard-of-care option in this setting. According to Moderna, the regimen is the first and only combination to show a clinically meaningful improvement over pembrolizumab alone.

The company post did not provide detailed efficacy figures or safety data. Moderna said it will continue to follow patients in the study and assess additional secondary endpoints, including overall survival.

Development program continues

Moderna and Merck are continuing to study intismeran autogene with pembrolizumab and with other anti-cancer therapies. The candidate is also being evaluated as monotherapy. Moderna said the broader program spans multiple tumor types and disease stages, including melanoma, lung, bladder and kidney cancers.

For the pharmaceutical and biotech sector, the announcement is notable because it points to the clinical maturation of individualized mRNA-based cancer therapies. Regulatory review remains a key next step. Moderna said it plans to engage with regulators about potential submissions.

mRNA platform moves further into oncology

Moderna noted that its mRNA platform has already led to five approved products, mainly in infectious diseases. The latest results bring oncology applications of the platform further into focus.

The announcement also contains several forward-looking statements. Whether and when intismeran autogene in combination with pembrolizumab could become available to patients outside clinical trials remains open.

Advertisement

Only a few physicians log in to your website?

Advertisement

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.


A Partner For Successful Marketing in Pharma & Healthcare

Advertisement

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.

Leading providers in pharma and healthcare marketing

Sponsored
  • MINTT Digital
  • 8awake
  • MINTT Digital

  • 8awake

    The leading Healthcare & Pharma-Marketing-Agency

Looking for a new partner in pharma and healthcare marketing?

Visit our agency finder

Copyright 2026 Pharma-Marketing.com.